Muscle-invasive bladder cancer historically necessitated radical cystectomy, the surgical removal of the bladder, as the standard of care; however, this procedure is not without profound consequences, including lifelong dependence on urinary diversion devices and a substantial decline in quality of life due to complications. The pursuit of bladder-sparing protocols has therefore become a crucial focus of oncologic innovation, aiming to maintain organ function while effectively controlling tumor progression.

Circulating tumor DNA comprises short fragments of DNA shed into the bloodstream by apoptotic or necrotic cancer cells, providing a non-invasive window into tumor dynamics. The Fox Chase team rigorously evaluated ctDNA as a surrogate marker for treatment response and disease recurrence in patients undergoing bladder preservation through a combination of chemotherapy and immunotherapy. The incorporation of immunotherapeutic agents, particularly nivolumab, represents a cutting-edge advancement, targeting immune checkpoint pathways that tumors exploit to evade immune surveillance.

In the RETAIN-2 trial, over seventy patients with MIBC were administered induction chemotherapy concurrent with nivolumab, followed by maintenance immunotherapy. This strategic combination aims to elicit robust tumor regression while fostering durable systemic immunity. Patients who demonstrated a pathologic complete response were spared immediate cystectomy, instead entering a vigilant surveillance protocol. Impressively, approximately 80% of these patients remained free from metastatic disease after a two-year follow-up period, affirming the efficacy of this approach.

A meticulous analysis of serial blood samples revealed that the presence of ctDNA following treatment was strongly correlated with the eventual development of distant metastases, making ctDNA a powerful prognostic tool for systemic disease risk. Importantly, patients who were ctDNA-negative post-treatment exhibited favorable clinical outcomes regardless of whether bladder removal was performed, emphasizing ctDNA’s potential to inform personalized therapeutic decisions.

Contrary to its utility in predicting metastasis, ctDNA did not reliably signal local tumor recurrence within the bladder. While a considerable subset of patients developed intravesical recurrences during surveillance, the majority did not exhibit ctDNA elevation prior to detection, highlighting a significant limitation in ctDNA’s sensitivity for local disease monitoring. This finding underscores the necessity for adjunctive biomarkers or imaging modalities capable of early identification of bladder-localized recurrence to complement ctDNA profiling.

This nuanced understanding of ctDNA’s capabilities enables oncologists to refine patient selection for bladder preservation strategies more safely and effectively. Incorporating ctDNA analysis into clinical decision-making facilitates a response-adapted framework whereby patients with undetectable ctDNA can be considered for organ-sparing treatment without compromising oncologic control. Conversely, ctDNA positivity may prompt more aggressive interventions or closer monitoring to preclude metastatic progression.

The implications of these findings extend beyond immediate clinical utility, illuminating pathways for future research and trial design. The Fox Chase investigators are poised to embark on the RETAIN-3 clinical trial, aimed at prospectively validating ctDNA as a biomarker to tailor neoadjuvant and adjuvant treatment regimens with heightened precision. Such biomarker-driven approaches epitomize the evolution toward personalized oncology, reducing overtreatment and enhancing patient quality of life.

Further longitudinal follow-up from RETAIN-2 participants will elucidate the long-term durability of bladder preservation and metastasis-free survival afforded by this innovative combination therapy. It will also provide critical insights into the kinetics of ctDNA and its relationship to treatment resistance and disease relapse.

The integration of ctDNA testing into the clinical management of MIBC represents a compelling evolution in bladder cancer care, enabling a more nuanced balance between effective oncologic control and organ preservation. This biomarker-driven strategy directly addresses patient-centered concerns about the functional and psychological burdens of radical cystectomy.

Dr. Pooja Ghatalia, the study’s lead author and Associate Professor at Fox Chase, emphasized the transformative potential of these findings: “Our data suggest that ctDNA can be a pivotal factor in clinical decision-making, guiding who may safely continue with bladder preservation and who requires more aggressive treatment. Nevertheless, we must continue to identify complementary biomarkers to effectively detect bladder-local recurrence early.”

Presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, these findings underscore the integration of tumor biology insights with immunotherapy advances to tailor bladder cancer treatment. This pioneering work may soon change the therapeutic landscape for thousands of patients with MIBC worldwide.

As bladder cancer research progresses, the convergence of molecular diagnostics such as ctDNA with evolving systemic therapies heralds a new era of precision medicine, optimizing survival outcomes while preserving patient autonomy and quality of life.

Subject of Research: Muscle-invasive bladder cancer and circulating tumor DNA as a biomarker for bladder-preserving treatment strategies.

Article Title: Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV).

News Publication Date: 27-Feb-2026

Web References: http://dx.doi.org/10.1200/JCO.2026.44.7_suppl.TPS893

Image Credits: Fox Chase Cancer Center

Keywords: Muscle-invasive bladder cancer, circulating tumor DNA, ctDNA, bladder preservation, neoadjuvant chemoimmunotherapy, nivolumab, metastatic risk, bladder-sparing treatment, RETAIN-2 clinical trial, immunotherapy, biomarkers, tumor recurrence

Cancer remains the predominant cause of disease-related mortality among children in the United States following infancy, with nearly 15,000 new pediatric and adolescent diagnoses projected for 2024 alone. Of these, approximately 1,500 young lives are tragically lost despite advances in therapy. BrightSeq responds to this urgent clinical challenge by engineering a comprehensive suite of assays designed explicitly for the molecular characterization of pediatric solid tumors and sarcomas. The program aims not only to enhance diagnostic accuracy but also to deliver prognostic insights that can inform targeted and personalized therapeutic interventions.

At the heart of BrightSeq’s scientific foundation lies the innovative work of the Crompton laboratory at Dana-Farber, which has elucidated the clinical utility of circulating tumor DNA (ctDNA) as a biomarker for pediatric solid malignancies. By leveraging liquid biopsy techniques, BrightSeq endeavors to enable minimally invasive monitoring of tumor burden and molecular evolution over treatment courses. This approach promises to revolutionize how pediatric cancers are detected, managed, and understood at the genomic level, transitioning from solely tissue-based diagnostics to dynamic, blood-based genomic surveillance.

The consortium’s operational framework is strategically distributed, reflecting the unique expertise and capabilities of each member institution. Boston Children’s Hospital will spearhead clinical variant interpretation and reporting workflows, translating complex genomic data into actionable clinical insights that can directly inform patient care. Broad Clinical Labs brings its state-of-the-art CLIA/CAP certified sequencing infrastructure and bioinformatics acumen to bear, meticulously validating and performing the genomic assays essential for comprehensive tumor profiling. Meanwhile, Dana-Farber Cancer Institute will leverage its expansive patient bases and consortia networks, championing cohort-based translational research and advancing innovative assay modalities tailored to pediatric oncology.

BrightSeq’s proprietary assay portfolio is engineered with scientific rigor and clinical applicability in mind. It encompasses comprehensive somatic whole exome sequencing (WES) of tumor specimens to detect a broad spectrum of genetic alterations implicated in oncogenesis. Complementing this, the platform employs ultra-low pass whole genome sequencing (ULPWGS) alongside custom hybrid-capture sequencing of liquid biopsy specimens. These technologies facilitate sensitive quantification of tumor-derived DNA fractions, enabling the detection of somatic variants with high fidelity, even at low abundance, which is critical for early detection and longitudinal disease monitoring.

Importantly, BrightSeq aims to seamlessly integrate this genomic information within clinical workflows, ensuring that the detection of medically actionable mutations is timely and informs treatment decisions. This integration is particularly vital in pediatric oncology, where therapeutic windows are narrow and precision-guided interventions can dramatically influence outcomes. The initiative also embodies a virtuous cycle of discovery and clinical implementation, whereby real-world patient data informs ongoing assay refinement and novel biomarker identification.

Leaders from each institution have vocalized their enthusiasm regarding the transformative potential of BrightSeq. Dr. Mark D. Fleming, Pathologist-in-Chief at Boston Children’s Hospital, emphasizes the initiative’s role in solidifying precision diagnostics for children, highlighting the immediate and substantial clinical and research benefits. Echoing this sentiment, Dr. Kimberly Stegmaier, Chair of Pediatric Oncology at Dana-Farber, underscores how the collaboration empowers researchers and clinicians to tackle the critical unmet needs in pediatric cancer therapeutics while maintaining a patient-centered focus through rapid result dissemination. Dr. Niall Lennon, Chair and Chief Scientific Officer at Broad Clinical Labs, heralds BrightSeq as a marriage of genomics innovation with scalable clinical operations, underscoring its dual mission of supporting both frontline care and foundational discovery science.

The establishment of BrightSeq reflects a broader evolution in oncology, where multi-institutional synergy accelerates translational genomics. Traditional silos between research and clinical entities often limit the pace at which novel assays transition into practice; BrightSeq’s integrative model dismantles these barriers. By combining clinical interpretation expertise, sequencing capability, and patient engagement within a coordinated ecosystem, it stands as a paradigm for future initiatives aimed at rare cancer subtypes.

Moreover, BrightSeq’s technological framework places significant emphasis on precision and sensitivity. The employment of ultra-low pass whole genome sequencing for liquid biopsies is particularly noteworthy. ULPWGS involves shallow sequencing depth across the entire genome, which, when paired with sophisticated computational algorithms, allows for accurate estimation of tumor DNA fractional content and structural variant detection at a cost-effective scale. This method enhances the ability to monitor minimal residual disease and clonal evolution dynamically, offering clinicians a near real-time picture of tumor biology.

The program’s ambition is not limited to diagnostics alone but extends into prognostics and therapeutic guidance. By capturing the somatic mutational landscape through whole exome and hybrid-capture strategies, BrightSeq can identify driver mutations and resistance mechanisms that influence disease course and response to treatment. This granular molecular insight will enable oncologists to stratify patients more effectively, tailor treatment modalities, and potentially identify candidates for emerging targeted therapies or clinical trials.

Furthermore, the pediatric focus of BrightSeq cannot be overstated. Pediatric cancers often harbor distinct genomic features compared with adult tumors, necessitating specialized assay designs and interpretative frameworks. The suite’s customization to childhood cancer biology addresses inherent challenges such as low tumor mutation burden and diverse histological subtypes. This targeted approach ensures that the assays are not merely adaptations of adult diagnostics but fully optimized for the pediatric oncology landscape.

Underlying the launch of BrightSeq is a recognition of the critical need for philanthropic support in advancing rare disease research. The initiative’s funding, drawn from generous donors, underscores the role of community engagement and investment in accelerating scientific innovation. This fiscal model enables sustained, cutting-edge research and development efforts that might otherwise be hampered by limited commercial incentives inherent in rare pediatric cancers.

In conclusion, BrightSeq epitomizes the forefront of precision pediatric oncology, weaving together state-of-the-art genomic technologies, cross-institutional expertise, and patient-centric goals. It promises to reshape diagnostic paradigms, improve prognostic accuracy, and catalyze novel therapeutic discovery—all while delivering tangible clinical impact for children confronting cancer. As this initiative unfolds, it is poised to serve as a beacon of innovation and hope within the pediatric oncology community and beyond.

Subject of Research: Pediatric oncology genomics, liquid biopsy, somatic tumor profiling, pediatric solid tumors and sarcomas.

Article Title: BrightSeq: A Revolutionary Collaborative Genomics Initiative Transforming Pediatric Cancer Diagnostics

News Publication Date: August 6, 2025

Web References:

• Boston Children’s Hospital: https://www.childrenshospital.org/
• Dana-Farber Cancer Institute: https://www.dana-farber.org/
• Broad Clinical Labs: https://broadclinicallabs.org/

Keywords: Pediatrics, Genomics, Human Genome Sequencing, Pediatric Cancer, Circulating Tumor DNA, Liquid Biopsy, Whole Exome Sequencing, Ultra-Low Pass Whole Genome Sequencing, Somatic Mutation Profiling, Translational Oncology, Precision Medicine, Pediatric Solid Tumors

HER2 (human epidermal growth factor receptor 2), encoded by the ERBB2 gene, has long been recognized for its pivotal role in breast and gastroesophageal cancers. Amplifications and overexpression of HER2 protein in these malignancies are well-characterized drivers, serving as prime targets for specific therapeutics. However, ERBB2 oncogenic point mutations, which appear in approximately 3.5% of diverse solid tumors, represent an underexplored frontier that carries promise for expanding targeted treatments beyond traditional HER2-amplified cancers.

The study involved a cohort of nineteen patients with refractory solid tumors carrying deleterious ERBB2 mutations, enrolled under the Copenhagen Prospective Personalized Oncology trial. Despite the variety of primary tumor types and prior treatments, each patient received HER2-targeted therapy tailored to exploit the vulnerabilities unveiled by comprehensive whole-exome sequencing (WES) and longitudinal ctDNA profiling. These genomic techniques allowed researchers to capture the dynamic changes in tumor genetics throughout treatment, providing a sophisticated portrait of evolving mutational landscapes.

Importantly, the analysis revealed an overall response rate (ORR) of 37% alongside a disease control rate (DCR) of 68%, and a median progression-free survival (PFS) of 4.4 months. These findings are remarkable given the heavily pretreated, molecularly heterogeneous nature of the cohort. A nuanced observation emerged when dissecting mutation locations within ERBB2: patients harboring oncogenic variants located in the tyrosine kinase domain exhibited a notably higher ORR of 60%, underscoring the therapeutic relevance of mutation topography in dictating drug sensitivity.

Clonality, defined by the proportion of tumor cells carrying a given variant, surfaced as a critical factor governing treatment success. Tumors in which ERBB2 mutations were clonal—present ubiquitously among cancer cells—demonstrated more pronounced responses compared to those with subclonal mutations. This distinction presents a compelling paradigm: targeting clonal driver mutations is far more efficacious, whereas subclonal diversification may contribute to treatment resistance and disease progression.

The study’s innovative use of sequential ctDNA monitoring further solidified the correlation between mutation burden and clinical outcomes. ctDNA, which circulates freely and reflects tumor-derived genetic material, provided a real-time, minimally invasive window into tumor evolution. Variations in ERBB2 mutation allele fractions in plasma mirrored therapeutic response and progression, highlighting ctDNA’s potential as a predictive and monitoring biomarker. As patients responded to therapy, circulating levels of ERBB2 mutations declined, whereas rising levels often heralded imminent resistance.

This temporal layer of molecular surveillance is a leap forward in personalized oncology, since it facilitates proactive treatment adaptations in response to genomic shifts. The integration of ctDNA with tumor tissue sequencing creates a powerful synergy that overcomes limitations inherent in single-timepoint biopsies, offering dynamic insights into tumor heterogeneity and clonal architecture that evolve under therapeutic pressure.

Notwithstanding exciting clinical implications, the researchers were candid about limitations. The small sample size and cohort heterogeneity—reflecting diverse tumor histologies and varied HER2-targeted regimens—necessitate cautious interpretation and underscore the need for larger, more homogeneous clinical trials. Nonetheless, the foundational proof-of-concept established here opens pathways for refining precision medicine approaches tailored to oncogenic ERBB2 variants beyond amplification.

At the molecular level, ERBB2 mutations often activate downstream signaling cascades such as PI3K/AKT and MAPK pathways, driving tumor proliferation and survival. Tyrosine kinase domain mutations, by altering receptor conformation and enhancing kinase activity, sensitize tumors to kinase inhibitors. The observed higher response rate in patients with these specific variants is consistent with mechanistic models predicting direct inhibition of aberrant signaling as a fruitful therapeutic strategy.

Future directions may include the development and clinical evaluation of next-generation HER2 inhibitors optimized to target variant-specific conformations, as well as combination regimens designed to overcome resistance mechanisms arising from tumor heterogeneity. Additionally, applying ctDNA-guided adaptive treatment algorithms in prospective trials could validate the utility of liquid biopsies for real-time therapeutic decision-making.

The study’s rigorous integration of comprehensive genomic profiling, longitudinal ctDNA analysis, and clinical endpoints exemplifies state-of-the-art oncology research. It further cements the concept that understanding mutational clonality and spatial-temporal tumor heterogeneity is critical in realizing the full potential of targeted therapy. As the field moves towards more individualized interventions, dissecting the subtle nuances of ERBB2 mutation biology offers a beacon of hope for patients with otherwise refractory solid tumors.

These findings underscore the imperative of incorporating precise genomic characterization into routine clinical workflows. By identifying patients with clonal HER2/ERBB2 mutations, clinicians can prioritize those most likely to benefit from HER2-targeted agents, mitigating unnecessary exposure to ineffective treatments. The promise of personalized intervention, grounded in molecular realities, continues to reshape cancer therapeutics with ever-increasing precision and efficacy.

In conclusion, this pioneering investigation translates molecular insights into tangible clinical benefits, advocating for expanded molecular testing of ERBB2 mutations in a broad spectrum of solid tumors. The correlation of mutation clonality, domain specificity, and dynamic ctDNA profiles with treatment outcomes paves the way for refined patient stratification and individualized treatment strategies. Despite challenges inherent in rare mutation subsets and tumor heterogeneity, HER2-targeted therapy emerges as a compelling option in this emerging therapeutic niche.

This research exemplifies the evolving paradigm wherein genomics and liquid biopsy converge to revolutionize cancer care. Ongoing studies will undoubtedly build upon these foundations to enhance our understanding of HER2-mutated tumors and optimize therapeutic algorithms. As molecular oncology ventures into previously uncharted territories, the lessons from ERBB2-mutated solid tumors beckon a new era of targeted precision medicine with significant clinical promise.

Subject of Research: Investigation of mutational landscape and therapeutic efficacy in HER2/ERBB2-mutated solid tumors utilizing tumor tissue sequencing and circulating tumor DNA analysis during HER2-targeted therapy.

Article Title: Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.

Article References:
Egebjerg, K., Spanggaard, I., Ahlborn, L.B. et al. Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors. BMC Cancer 25, 1272 (2025). https://doi.org/10.1186/s12885-025-14599-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14599-7